Activating mutations of the gp130/JAK/STAT pathway in human diseases

Adv Protein Chem Struct Biol. 2019:116:283-309. doi: 10.1016/bs.apcsb.2018.11.007. Epub 2018 Dec 27.

Abstract

Cytokines of the interleukin-6 (IL-6) family are involved in numerous physiological and pathophysiological processes. Dysregulated and increased activities of its members can be found in practically all human inflammatory diseases including cancer. All cytokines activate several intracellular signaling cascades, including the Jak/STAT, MAPK, PI3K, and Src/YAP signaling pathways. Additionally, several mutations in proteins involved in these signaling cascades have been identified in human patients, which render these proteins constitutively active and result in a hyperactivation of the signaling pathway. Interestingly, some of these mutations are associated with or even causative for distinct human diseases, making them interesting targets for therapy. This chapter describes the basic biology of the gp130/Jak/STAT pathway, summarizes what is known about the molecular mechanisms of the activating mutations, and gives an outlook how this knowledge can be exploited for targeted therapy in human diseases.

Keywords: Activation; Interleukin-6; Jak1; Jak2; STAT3; gp130.

Publication types

  • Review

MeSH terms

  • Animals
  • Cytokine Receptor gp130 / genetics
  • Cytokine Receptor gp130 / immunology*
  • Humans
  • Inflammation / genetics
  • Inflammation / immunology
  • Interleukin-6 / genetics
  • Interleukin-6 / immunology
  • Janus Kinases / genetics
  • Janus Kinases / immunology*
  • Mutation
  • Neoplasms / genetics
  • Neoplasms / immunology
  • STAT Transcription Factors / genetics
  • STAT Transcription Factors / immunology*
  • Signal Transduction

Substances

  • Interleukin-6
  • STAT Transcription Factors
  • Cytokine Receptor gp130
  • Janus Kinases